Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer and Pre-existing Autoimmune Disease

Inclusion criteria

• ✓. Age \> 18
• ✓. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1
• ✓. Metastatic, locally advanced or recurrent NSCLC, not amenable to curative therapy.
• ✓. Patients should have received at least one platinum-based chemotherapy regimen for recurrent or metastatic disease or have received platinum-based chemotherapy as part of adjuvant or neoadjuvant therapy and experienced progression of disease within 6 months of completing therapy.
• ✓. Patients with tumor genetic alterations such as EGFR, ALK, ROS1 or BRAF V600E alterations for which there is FDA-approved targeted therapy must have been treated with the appropriate targeted inhibitors in prior therapy
• ✓. No limit on number of prior therapies
• ✓. Ability to provide written, informed consent
• ✓. Patients must be on a stable regimen of treatment for their autoimmune condition without need for addition of new medications or escalating doses of preexisting medications in the previous 12 weeks prior to study entry

Exclusion criteria